Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Opus Genetics Posts $46.5 Million Third-Quarter Net Loss

None

Opus Genetics (IRD) reported third-quarter 2026 license and collaborations revenue of $1.1 million and a net loss of $46.5 million, or $0.46 per basic and diluted share. The company reported cash and cash equivalents of $89.0 million as of September 30, 2026.

The company completed dosing in the high-dose Cohort 2 of its OPGx-BEST1 Phase 1/2 trial and expects topline data in the first quarter of 2027. Its OPGx-LCA5 registrational Phase 3 trial is fully enrolled, with dosing expected to begin in the fourth quarter of 2026.

  • Third-quarter revenue was $1.1 million, compared with $3.1 million in the prior-year period.
  • R&D expense was $14.5 million, while G&A expense was $5.9 million.
  • OPGx-BEST1 Cohort 2 enrolled and dosed 11 participants.
  • The FDA cleared the IND for OPGx-RDH12, with Phase 1/2 dosing planned for the fourth quarter of 2026.
  • FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia triggered a milestone payment from Viatris.

$IRD Insider Trading Activity

IRD Insider Trades

$IRD insiders have traded $IRD stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.

Here’s a breakdown of recent trading of $IRD stock by insiders over the last 6 months:

  • FIGHTING BLINDNESS RETINAL DEGENERATION FUND FOUNDATION has made 0 purchases and 2 sales selling 2,256,000 shares for an estimated $10,150,980.
  • ROBERT E. GAGNON (Chief Financial Officer) has made 0 purchases and 3 sales selling 49,783 shares for an estimated $199,803.
  • GEORGE MAGRATH (Chief Executive Officer) has made 0 purchases and 3 sales selling 47,324 shares for an estimated $172,492.
  • BENJAMIN R YERXA (President) has made 0 purchases and 3 sales selling 40,618 shares for an estimated $139,428.
  • JOSEPH K SCHACHLE (Chief Operating Officer) has made 0 purchases and 2 sales selling 9,411 shares for an estimated $30,647.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$IRD Hedge Fund Activity

We have seen 73 institutional investors add shares of $IRD stock to their portfolio, and 29 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles